Cargando…

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2

OBJECTIVES: To identify the most efficacious timing for tocilizumab administration in critically ill patients infected with severe acute respiratory syndrome coronavirus-2. DESIGN: Observational multicenter cohort study. SETTING: A total of 23 acute care hospitals in four states. PATIENTS: One-hundr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrak, Russell M., Van Hise, Nicholas W., Skorodin, Nathan C., Fliegelman, Robert M., Chundi, Vishnu, Didwania, Vishal, Han, Alice, Harting, Brian P., Hines, David W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Clinical Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009634/ https://www.ncbi.nlm.nih.gov/pubmed/33817660 http://dx.doi.org/10.1097/CCE.0000000000000395

Ejemplares similares

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2
por: Petrak, Russell M., et al.
Publicado: (2021)

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
por: Van Hise, Nicholas, et al.
Publicado: (2020)

Value and Clinical Impact of an Infectious Disease-Supervised Outpatient Parenteral Antibiotic Therapy Program
por: Petrak, Russell M., et al.
Publicado: (2016)

838. Oral Vancomycin Prophylaxis Works!
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

740 Hospital Avoidance Utilizing an ID Supervised OPAT Program
por: Skorodin, Nathan, et al.
Publicado: (2014)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
por: Van Hise, Nicholas W., et al.
Publicado: (2020)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Tocilizumab in critically ill COVID-19 patients: An observational study
por: Mushtaq, Muhammad Z., et al.
Publicado: (2022)

Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients
por: Cala-García, Juan David, et al.
Publicado: (2020)

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
por: Bhandari, Sudhir, et al.
Publicado: (2021)

Association of Tocilizumab and Invasive Aspergillosis in Critically Ill Patients with Severe COVID-19 Pneumonia and Acute Respiratory Distress Syndrome
por: Wu, Kuo-Lun, et al.
Publicado: (2022)

Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
por: Dufranc, Etienne, et al.
Publicado: (2020)

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19
por: Zacharias, Harry, et al.
Publicado: (2022)

Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
por: Camou, Fabrice, et al.
Publicado: (2022)

Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
por: Szabo, Robert, et al.
Publicado: (2023)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Critically ill patients with Middle East respiratory syndrome coronavirus infection
por: Al-Dorzi, Hasan M., et al.
Publicado: (2016)

Critically Ill Patients with Middle East Respiratory Syndrome Coronavirus Infection
por: Al-Dorzi, H. M., et al.
Publicado: (2016)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023)

Tocilizumab: Invasive pulmonary aspergillosis following off-label use of tocilizumab for severe acute respiratory coronavirus-2 infection: case report
Publicado: (2021)

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
por: Huang, Edmund, et al.
Publicado: (2021)

Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
por: Han, Alice, et al.
Publicado: (2021)

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
por: Hafez, Wael, et al.
Publicado: (2022)

The Viral Infection and Respiratory Illness Universal Study (VIRUS): An International Registry of Coronavirus 2019-Related Critical Illness
por: Walkey, Allan J., et al.
Publicado: (2020)

Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in “non-critically-ill” patients on hemodialysis
por: Castellano, Giuseppe, et al.
Publicado: (2020)

Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2
por: Banday, Aaqib Zaffar, et al.
Publicado: (2021)

Interhospital Transfer of Critically Ill Patients Because of Coronavirus Disease 19–Related Respiratory Failure
por: Allen, Rebecca, et al.
Publicado: (2020)

Dysregulated Host Response in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Critical Illness
por: Tiwari-Heckler, Shilpa, et al.
Publicado: (2021)

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
por: Zhang, Shengyu, et al.
Publicado: (2020)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
por: Mady, Ahmed, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases
por: ElSeirafi, Mohamed M, et al.
Publicado: (2020)

Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers
por: Atallah, Bassam, et al.
Publicado: (2020)

What's New in Critical Illness and Injury Science? Mortality effects of tocilizumab for patients admitted with COVID-19 pneumonia
por: Miller, Andrew C., et al.
Publicado: (2021)

The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study
por: Korayem, Ghazwa B., et al.
Publicado: (2022)

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
por: Hartog, Nicholas L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jbceh55q89uvq8eg5p6bhl5chg